RNA Disruption Assay (RDA) Response Prediction in Neoadjuvant Chemotherapy Breast Cancer Treatment

NCT02190227 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Invasive Breast Cancer

Interventions

DEVICE: Tumor RDA biopsy

Sponsor

Jewish General Hospital

Collaborators

[object Object]